Spyre Therapeutics to Participate in Upcoming June Investor Conferences

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on developing antibody treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases, has announced its participation in two major healthcare investor conferences in June 2025.

The company will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 8:10am ET, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20am ET. Live webcasts and replays will be accessible through Spyre's investor relations website.

News Market Reaction – SYRE

+0.60%

+0.60% Session move

In the trading session that priced this news, SYRE gained 0.60%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., May 28, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences:

Event: Jefferies Global Healthcare Conference
Date: Wednesday, June 4, 2025
Fireside Time: 8:10am ET

Event: Goldman Sachs 46th Annual Global Healthcare Conference 2025
Date: Monday, June 9, 2025
Fireside Time: 9:20am ET

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.

Follow Spyre Therapeutics on social media: @spyretx and LinkedIn

View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-june-investor-conferences-302464699.html

SOURCE Spyre Therapeutics, Inc.

FAQ

What investor conferences will Spyre Therapeutics (SYRE) attend in June 2025?

Spyre Therapeutics will participate in the Jefferies Global Healthcare Conference on June 4, 2025, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025.

What time is Spyre Therapeutics' (SYRE) presentation at the Jefferies Healthcare Conference?

Spyre Therapeutics will present at the Jefferies Global Healthcare Conference at 8:10am ET on June 4, 2025.

What is Spyre Therapeutics' (SYRE) main focus area for drug development?

Spyre Therapeutics focuses on developing antibody treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases.

Where can investors watch Spyre Therapeutics' (SYRE) conference presentations?

Investors can access live webcasts and replays of the presentations through Spyre's investor relations website at https://ir.spyre.com/events-and-presentations.